Pfizer Announce Positive Preliminary Phase III Clinical Results

Pfizer yesterday announced positive results from their phase III clinical trial comparing prophylaxis regimen of BeneFIX Coagulation Factor IX (Recombinant) 100 IU/kg once-weekly, with on-demand treatment for moderately severe to severe hemophilia B. Top-line results showed that the clinical trial met its primary endpoint, with a statistically noteworthy reduction in the annualised bleeding rate in

Continue Reading

UK Government & Pharma Invest £52 Million to Improve UK Science Skills

David Willetts, the UK’s Science Minister, yesterday announced an investment of £52 million for the UK’s science sectors to improve skills and vocational training. The announcement was made at the official launch of the Science and Industrial Partnership (SIP), which is being led by GlaxoSmithKline (GSK). The announcement is expected to create over ‘7,800 education

Continue Reading

Vertex Report Positive Results for Cystic Fibrosis Combo

Vertex have announced positive late-stage clinical trial results for their drug combo to treat cystic fibrosis (CF), taking a leap closer to regulatory filing. Vertex confirmed that the combination of lumacaftor and Kalydeco, resulted in statistically significant improvements in lung function compared to placebo, for patients aged 12 years and over with two copies of

Continue Reading

Positive Clinical Trial Results for Novartis’ Signifor

Novartis have released data from a phase III clinical trial suggesting that their somatostatin analogue, Signifor, could be effective for the growth hormone disorder, acromegaly. The recent clinical trial assessed a once-monthly intramuscular formulation, named Signifor LAR, in patients with acromegaly where standard therapies had been ineffective.  Signifor has already been approved by regulators in

Continue Reading

ViiV’s HIV Drug, Tivicay, Launched in the UK

diagnosis Tivicay, Launched in the UK” src=”http://i57.tinypic.com/2re6t69.jpg” width=”164″ height=”147″ />HIV patients in the UK will from this week have another treatment option after ViiV Healthcare announced the launch of their once-daily drug, Tivicay (dolutegravir). The integrase inhibitor was approved in Europe last month for HIV-1 in a broad patient population of treatment-naive and treatment-experienced adults

Continue Reading

Auxilium Pharmaceuticals’ Xiaflex Approved by FDA

The US Food and Drug Administration (FDA) announced on Friday that they have approved Auxilium Pharmaceuticals’ Xiaflex to treat Peyronie’s disease, which causes painful, curved erections in men. Xiaflex (collagenase clostridium histolyticum) is the first FDA-approved non-surgical treatment option for men with Peyronie’s disease, who have a plaque in the penis that results in curvature

Continue Reading

Merck Announce Cut of 8,500 Jobs

troche 500 Jobs” src=”http://img217.imageshack.us/img217/6978/merck.png” width=”156″ height=”52″ />Merck & Co have unveiled plans to cut around 8,500 jobs,  in addition to previously-announced cuts of 7,500 roles, in an attempt to decrease costs and improve competitiveness. Merck are expecting to make $2.50 billion in yearly cost savings by the end of 2015 and the majority of this

Continue Reading